A review of pharmacogenetic studies in the Bangladeshi population
| Autor: | Md. Shaki Mostaid, Md. Abdul Aziz, Jeba Atkia Maisha, Mohammad Safiqul Islam, Abdullah Al Maruf |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Drug Metabolism and Personalized Therapy. |
| ISSN: | 2363-8915 2363-8907 |
| DOI: | 10.1515/dmpt-2022-0194 |
| Popis: | Pharmacogenetics (PGx)-guided prescribing is an evidence-based precision medicine strategy. Although the past two decades have reported significant advancements in both the quality and quantity of PGx research studies, they are seldom done in developing countries like Bangladesh. This review identified and summarized PGx studies conducted in the Bangladeshi population by searching PubMed and Google Scholar. Additionally, a quality evaluation of the identified studies was also carried out. Eleven PGx studies were identified that looked at the effects of genetic variants on blood thinners (CYP2C9, VKORC1, and ITGB3), cancer drugs (TPMT, MTHFR, DPYD, ERCC1, GSTP1, XPC, XRCC1, TP53, XPD, and ABCC4), statins (COQ2, CYP2D6, and CYP3A5), and prednisolone (ABCB1, CYP3A5, and NR3C1) in the Bangladeshi population. Most studies were of low to moderate quality. Although the identified studies demonstrated the potential for PGx testing, the limited PGx literature in the Bangladeshi population poses a significant challenge in the widespread implementation of PGx testing in Bangladesh. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|